Cover Image

The rising fear of Wuhan Virus ‘2019-nCoV’

Vengadesh Letchumanan, Hooi-Leng Ser, Jodi Woan-Fei Law, Loh Teng-Hern Tan, Bey-Hing Goh, Nurul Syakima Ab Mutalib, Learn-Han Lee Abstract - 1254 PDF - 12

Abstract


The “Wuhan Virus” was first recognized in the beginning of December 2019 and identified as a new type of coronavirus 2019-nCoV. This coronavirus-induced pneumonia originated from Wuhan (China), and has spread across 27 countries, infected 17,488 people and caused 362 deaths, at the this Editorial went to press. The transmission of 2019-nCoV to individuals of different countries is predominantly through close contact with an infected person. The experts around the global raise the concern on the rising number of infected cases and deaths, and increased the effort to produce an effective drug or vaccine for this virus. Several efforts have been done to aid the detection of the virus and treatment of patients: 2019-nCoV detection kits (BGI), and development of two new hospital, and treating patients with combination of antiviral for flu and HIV. In the United States, doctors successfully treated a 2019-nCoV patient with Gilead Sciences drug – remdesivir, however further test need to be done to confirm the effectiveness of these antivirals. Hopefully, the pharmaceutical companies with the team of researchers will be able to discover an effective vaccine to treat coronavirus 2019-nCoV.  


Full Text:

PDF


DOI: https://doi.org/10.36877/pmmb.a0000053

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Vengadesh Letchumanan, Hooi-Leng Ser, Jodi Woan-Fei Law, Loh Teng-Hern Tan, Bey-Hing Goh, Nurul Syakima Ab Mutalib, Learn-Han Lee

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.